A novel approach to arterial thrombolysis

Blood

Volumn 94, Issue 8, 1999, Pages 2735-2743

  Klement, Petr ^a   Liao, Peng ^a   Bajzar, Laszlo ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; ANTIFIBRINOLYTIC AGENT; CARBOXYPEPTIDASE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PEPTIDE HYDROLASE INHIBITOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POTATO; PRIORITY JOURNAL; RABBIT;

EID: 0032877624     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.8.2735.420k30_2735_2743     Document Type: Article

References (50)

1. deWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897, 1980
2. Topol EJ: Toward a new frontier in myocardial reperfusion therapy; Emerging platelet preeminence. Circulation 97:211, 1998
3. Chesebro JH, Knauer DJ, Roberts R: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142, 1987
4. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med 329:1615, 1993
5. Hanna GP, Smalling RW: Therapy with thrombolytic agents in coronary artery disease. Curr Opin Cardiol 13:267, 1998
6. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E: TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 95:351, 1997
7. The global use of strategies to open occluded coronary arteries (GUSTO III) investigators: Comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118, 1998
8. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA: Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. N Engl J Med 77:142, 1988
9. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER: Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72:616, 1988
10. Minnema MC, Friederich P W, Levi M, von dem Borne PAKr, Mosnier LO, Meijers JCM, Blemond BJ, Hack CE, Bouma BN, ten Cate H: Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 101:10, 1998
11. Collins R, MacMahon S, Flather M, Baigen C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R: Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systemic overview of randomised trial. Br Med J 313:652, 1996
12. Kumar R, Beguin S, Hemker C: The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 74:962, 1995
13. Kumar R, Beguin S, Hemker C: The influence of fibrinogen and fibrin on thrombin generation. Thromb Haemost 72:713, 1994
14. White H, Aylward P, Frey M, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown A, French JK, Collins R, Maraganore J, Adelman B: A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 96:2155, 1997
15. The global use of strategies to open occluded coronary arteries investigators: A comparison of recombinant hirudin with heparin for the treament of acute coronary syndromes. N Engl J Med 335:775, 1996
16. The global use of strategies to open occluded coronary arteries investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631, 1994
17. Antman EM, for the TIMI 9A investigators: Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624, 1994
18. Nehaus KL, Essen RV, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the arbeitsgemeinschaft Leitender Kardiologischer Krankenausarzte (ALKK). Circulation 90:1638, 1994
19. Refino CJ, Schmitt D, Pater C, Eaton D, Bunting S: A carboxy-peptidase inhibitor markedly improves the potency of tPA in vivo. Fibrinol Proteolysis 12:29, 1998 (abstr)
20. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D: Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 269:21833, 1991
21. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 270:14477, 1995
22. 21a. Wang W, Hendriks DF, Scharpe SS: Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 269:15937, 1994
23. Bajzar L, Morser J, Nesheim ME: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603, 1996
24. Bajzar L, Nesheim ME, Morser J, Tracy PB: Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 273:2792, 1998
25. Nesheim ME, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L: Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386, 1997
26. Kokame K, Zheng X, Sadler JE: Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 273:12135, 1998
27. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88:2093, 1996
28. Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 96:2534, 1995
29. Ryan CA: Purification and properties of a carboxypeptidase inhibitor from potatoes. J Biol Chem 249:5495, 1974
30. Hass GM, Ryan CA: Carboxypeptidase inhibitor from potatoes. Methods Enzymol 80:778, 1981
31. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME: A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273:27176, 1998
32. Sakharov DV, Plow EF, Rijken DC: On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272:14477, 1997
33. Suenson E, Lutzen O, Thorsen S: Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513, 1984
34. de Vries C, Veerman H, Pannekoek H: Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. J Biol Chem 264:12604, 1989
35. Horrevoets AJG, Pannekoek H, Nesheim ME: A steady-state template model that describes the kinetics of fibrin-stimulated Glu1-and Lys78-plasminogen activation by native tissue type plasminogen activator and variants that lack either the Finger or Kringle 2 domain. J Biol Chem 272:2183, 1997
36. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J: The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 68:64, 1992
37. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR: Tissue factor prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 92:3323, 1995
38. Proctor RR, Rapaport SI: The partial thromboplastin time with kaolin. Am J Clin Pathol 36:212, 1961
39. Seegers WH, Smith HP: Factors which influence the activity of purified thrombin. Am J Physiol 137:348, 1942
40. Clauss A: Gerinnugphysiologische Schnellmethode zur bestimmung des fibrinogens. Acta Haematol 17:237, 1957
41. Teger-Nilsson AC, Frieberger P, Gyzander E: Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 37:403, 1977
42. Bajzar L, Fredenburgh JC, Nesheim ME: The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 265:16948, 1990
43. Neville DM: Molecular weight determination of protein-dodecyl; sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem 246:6328, 1971
44. Towbin H, Staehlin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350, 1979
45. Bajzar L, Taylor F, Tracy PB: A baboon model can be used to assess the physiologic function of TAFI. Thromb Haemost Suppl 77:596, 1997 (abstr)
46. Wang M, Nagashima M, Morser J: Thrombin-activatable fibrinolysis inhibitor slows clot lysis in rats, rabbits and dogs. Fibrinol Proteolysis 12:12, 1998 (abstr)
47. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF: Inducible Carboxypeptidase activity. A role in clot lysis in vivo. Circulation 93:1328, 1996
48. Jordan SP, Waxman L, Smith DE, Vlasuk GP: Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 29:11095, 1990
49. Krishnaswamy S, Vlasuk GP, Bergum PW: Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by Tick anticoagulant peptide. Biochemistry 33:7897, 1994
50. Colucci M, D'Aprile AM, Gresele P, Semeraro N: Effect of TAFI activation on clot lysis by pharmacological concentrations of t-PA. Fibrinol Proteolysis 12:12, 1998 (abstr)